Compare NOAH & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NOAH | ENGN |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | China | Canada |
| Employees | N/A | 82 |
| Industry | Investment Managers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.4M | 647.1M |
| IPO Year | 2010 | N/A |
| Metric | NOAH | ENGN |
|---|---|---|
| Price | $10.02 | $7.59 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 6 |
| Target Price | $11.00 | ★ $21.08 |
| AVG Volume (30 Days) | 184.1K | ★ 239.1K |
| Earning Date | 05-27-2026 | 03-09-2026 |
| Dividend Yield | ★ 5.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | $13.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.27 | $2.66 |
| 52 Week High | $12.84 | $12.25 |
| Indicator | NOAH | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 35.65 | 53.53 |
| Support Level | $9.64 | $6.04 |
| Resistance Level | $12.26 | $8.14 |
| Average True Range (ATR) | 0.42 | 0.51 |
| MACD | 0.00 | 0.18 |
| Stochastic Oscillator | 15.03 | 98.21 |
Noah Holdings Ltd is a wealth management service provider offering comprehensive advisory services on investment and asset allocation, mainly for Mandarin-speaking high-net-worth (HNW) investors. The company's operating segments are Domestic public securities, Domestic asset management, Domestic insurance, Overseas wealth management, Overseas asset management, Overseas insurance and comprehensive services, and Headquarters. Maximum revenue is generated from its Domestic asset management business, which manages private equity funds, real estate equity funds, and private secondary products. The domestic asset management operations focus on managing primary market exits and cross-border ETF products in the secondary market. Geographically, it derives maximum revenue from Mainland China.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.